Table 4.
Blood sample data for patients with minimum 6 h of fasting
| Pre UFH injection | Post UFH injection | ||||
|---|---|---|---|---|---|
| FPG (mg/dL) | IRI (μU/mL) | FFA (μEq/L) | IRI (μU/mL) | FFA (μEq/L) | |
| Group A1 | 88.3 ± 6.0 | 4.04 ± 2.53 | 432.1 ± 296.1 | 4.46 ± 2.86 | 1804.2 ± 739.7* |
| Group A2 | 95.3 ± 17.2 | 3.55 ± 3.08 | 733.7 ± 276.8 | 4.47 ± 2.21 | 2110.8 ± 691.5* |
| P value | .052 | .23 | .0023 | .60 | .26 |
Group A1: patients who had positive diffuse LV FDG uptake. Group A2: patients who had negative diffuse LV FDG uptake
UFH, unfractionated heparin; FPG, fasting plasma glucose; IRI, immunoreactive insulin; FFA, free fatty acid; LCD, low-carbohydrate diet
*P < .0001 vs before UFH administration (group A1) and negative (group A2)